Melim Catarina, Jarak Ivana, Veiga Francisco, Figueiras Ana
1Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal.
2REQUIMTE/LAQV, Group of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.
3 Biotech. 2020 Apr;10(4):147. doi: 10.1007/s13205-020-2142-5. Epub 2020 Mar 2.
Osteosarcoma (OS) is a rare aggressive bone, presenting low patient survival rate, high metastasis and relapse occurrence, mostly due to multi-drug resistant cells. To surpass that, the use of nanomedicine for the targeted delivery of genetic material, drugs or both have been extensively researched. In this review, we address the current situation of the disorder and some gene therapy options in the nanomedicine field that have been investigated. Among them, polymeric micelles (PM) are an advantageous therapeutic alternative highly explored for OS, as they allow for the targeted transportation of poorly water-soluble drugs to cancer cells. In addition, micelleplexes are PMs with cationic properties with promising features, such as the possibility for a dual therapy, which have made them an attractive research subject. The aim of this review article is to elucidate the application of a micelleplex formulation encapsulating the underexpressed miRNA145 to achieve an active targeting to OS cells and overcome multi-drug resistance, as a new and viable therapeutic strategy.
骨肉瘤（OS）是一种罕见的侵袭性骨肿瘤，患者生存率低，转移和复发率高，主要原因是存在多药耐药细胞。为了克服这一问题，利用纳米药物靶向递送遗传物质、药物或两者的研究已广泛开展。在本综述中，我们阐述了该疾病的现状以及纳米医学领域中一些已被研究的基因治疗方案。其中，聚合物胶束（PM）是一种针对骨肉瘤被广泛探索的有利治疗选择，因为它们能够将水溶性差的药物靶向运输至癌细胞。此外，胶束复合物是具有阳离子特性的聚合物胶束，具有如双重治疗可能性等有前景的特性，这使其成为一个有吸引力的研究对象。这篇综述文章的目的是阐明一种包裹低表达miRNA145的胶束复合物制剂的应用，以实现对骨肉瘤细胞的主动靶向并克服多药耐药性，作为一种新的可行治疗策略。
